Linghui Wang1,2†
Xi Zhu2†
Shuting Xu2,3Bin Zhou2Yong Wu2Zhouting Li2
Yanjie Zhao2Shuhui Li2Feng Cheng2
Lei Zhu2*- 1Graduate Joint Training Base of Zhejiang Chinese Medical University (Lishui Joint Training Base - Lishui Municipal Central Hospital), Hangzhou, Zhejiang, China
- 2Department of Head and Neck Surgery, The Fifth Hospital Affiliated to Wenzhou Medical University, Lishui Central Hospital, Lishui, Zhejiang, China
- 3Hangzhou Medical College, Hangzhou, Zhejiang, China
Hashimoto’s thyroiditis (HT) is a chronic autoimmune thyroiditis characterized by thyroid-specific autoantibodies (TPOAb, TGAb) positivity and lymphocytic infiltration, and is a major cause of hypothyroidism in iodine-sufficient regions. Epidemiological data show a significant increase in the prevalence of HT, which is about four times more common in adult women than in men. The pathogenesis of HT involves a complex interaction of genetic susceptibility, environmental factors, and immune regulation. Its clinical diagnosis is mainly based on serological tests (TPOAb/TGAb) and thyroid ultrasound features. The current treatment of Hashimoto’s is based on levothyroxine (T4) replacement. This article presents a narrative review of the pathogenesis, status, and challenges of treatment of HT to provide a theoretical basis for optimizing clinical practice and basic research.
Introduction
Hashimoto’s thyroiditis (HT) is characterized by thyroid peroxidase antibody(TPOAb) and thyroglobulin antibody (TGAb) positivity, lymphocytic infiltration, and progressive hypothyroidism (1–3); it is one of the most common organ-specific autoimmune diseases (4). In recent years, the prevalence of HT has increased significantly worldwide, especially in iodine-sufficient areas, and the incidence of HT in adult females can be 4–10 times higher than that in males, making it an increasingly serious public health problem (5). The pathogenesis of HT is characterized by the triple interaction of genetics-environment-immunity (1). The complex pathogenesis of HT, which results in a highly heterogeneous clinical presentation, with the clinical symptoms ranging from positive subclinical antibodies to significant hypothyroidism, spans several decades, making early diagnosis and intervention very difficult.
Currently, three major bottlenecks still exist in clinical diagnosis and treatment: first, the traditional diagnostic model relying on antibody detection and ultrasound has a limited ability to predict the progression of the disease; secondly, levothyroxine(LT4) replacement therapy can correct hypothyroidism but cannot block the autoimmune process; and thirdly, there is a lack of consensus on the intervention strategy for patients with subclinical stage. With the application of single-cell sequencing, artificial intelligence, and other technologies, the study of HT is moving towards a new stage of molecular typing and precision medicine. In this article, we review the pathogenesis, current status of diagnosis and treatment of HT, and other related research progress, aiming to provide new perspectives for optimizing clinical practice and translational research.
Background and epidemiology
Hashimoto’s thyroiditis is an autoimmune disease characterized by the persistent presence of specific autoantibodies (thyroid peroxidase antibodies and thyroglobulin antibodies) as well as lymphocytic infiltration, also known as autoimmune or chronic lymphocytic thyroiditis (1, 6, 7). In iodine-deficient regions, HT is the main cause of hypothyroidism, and Hashimoto’s is also characterized by hypothyroidism (2, 3). The incidence of HT is on the rise globally, with a prevalence of only 2% a decade or so ago, but today the prevalence of the disease is 5-10% (8, 9). Adult females have approximately four times the risk of HT compared to adult males. And according to a study in the UK, the age at which autoimmune diseases, including HT are diagnosed is concentrated at around 54 years of age (5). In addition, HT is a potential risk factor for thyroid cancer (10). The increasing incidence of HT has necessitated a more in-depth understanding of the disease to diagnose and intervene in its development accurately.
Etiology and pathogenesis
Hashimoto’s thyroiditis is an organ-specific autoimmune disease (4), and its pathogenesis involves the interaction of environmental, genetic, and immunological factors (1). In recent years, more and more studies have shown that the core pathological process of the disease is the abnormal recognition and attack of thyroid antigens by the immune system, leading to an imbalance of immune homeostasis and the development of autoimmune diseases (11). For example, autoreactive T cells trigger a humoral response in some susceptible individuals, generating antibodies against thyroid antigens (12), which in turn destroy the follicular cells of the thyroid and cause them to become hypothyroid; Th1 cells in the Th1/Th2 subset of helper T cells mediate the cellular immune response through activation of delayed-acting hypersensitivity, while Th2 regulates antibody production and humoral immune response, resulting in a cellular imbalance that leads to apoptosis of thyroid follicular cells (13). In addition, certain strains of intestinal flora, such as Lactobacillus, can increase the number of Th17 cells capable of expressing pro-inflammatory factors to alter the ratio of Th17 cells to Tregs, thereby disrupting immune homeostasis; a meta-analysis revealed that patients with Hashimoto’s thyroiditis have a higher gut microbiota richness index compared to healthy controls, while beneficial bacterial species such as Bifidobacterium are relatively reduced (14–16). Thus, this evidence implicates gut microbiota as a contributing factor in Hashimoto’s thyroiditis.
In the 1970s, the HLA gene was first found to be associated with HT (17), and as genetic techniques continue to evolve, the understanding of the disease has expanded from single-gene correlations to multi-gene interactions. Currently, genetic factors are broadly classified into three categories, namely human major histocompatibility complex genes, immunomodulatory genes, and thyroid-specific genes (18). As early as the 1990s, it was established that HLA-DR in the human major histocompatibility complex (MHC) class II genes is associated with susceptibility to the disease and also has a strong genetic association with the disease (19, 20). HLA is the most common gene associated with the onset of HT, with HLA-DR3 being the main risk haplotype in Caucasians and being more pronounced in the over-50-year-old female population, while HLA-DR5 is significantly associated with Asian populations (14, 21–23).In addition, NFE2L2 and SELENOS alleles, cytotoxic T-lymphocyte antigen 4(CTLA-4), FOXP3, and intracellular tyrosine phosphatase (PTPN22) have been associated with the risk of Hashimoto’s (24–27). Genetic variants enhance the binding of self-peptides to MHC by altering the process of autoantigen presentation and amplify the stimulation of T-cells, which in turn affects the normal function of thyroid cells (18). Furthermore, genetic variations in thyroid-specific genes-including the thyrotropin receptor (TSHR), thyroglobulin gene (TG), and thyroid peroxidase gene (TPO), play a key role in the development of the disease (28). These genes encode thyroid functions and can exacerbate thyroid follicular destruction in HT patients by altering the structure and expression levels of the corresponding antigens, thereby driving the development of HT (29). The rs4411444 GG genotype and the rs4903961 C allele in the TSHR gene enhancement region are most closely associated with this disease (30). Also, thyroid-specific genes are expressed in the central nervous system, allowing the development of Hashimoto encephalopathy (31). In addition to the above genes, recent studies have found that genes such as those encoding the vitamin D receptor, those involved in selenium metabolism, and those related to microbial susceptibility are also associated with the development of Hashimoto’s (32–35).
Although immune and genetic factors are predominant in the pathogenesis of HT, the triggering role of environmental factors is also indispensable. Among these factors, environmental influences such as excessive iodine intake, viral infections, and vitamin D deficiency contribute to the thyroid autoimmune response by disrupting immune tolerance and synergizing with genetic predispositions to cause the disease. Iodine is a component of thyroid hormones, thyroxine (T4) and triiodothyronine (T3), and is a key player in thyroid hormone synthesis in thyroid follicular cells (36); however, excessive iodine intake also increases the risk of autoimmune thyroid disease (37). Viral infections cause HT by triggering an immune response in the host that activates autoreactive T cells (38). Vitamin D plays a role in the autoimmune process and thus in the development of autoimmune diseases (39).
In conclusion, the pathogenesis of HT is the result of a dynamic interaction between immune intolerance, genetic susceptibility, and environmental triggers. Genetic variants provide the basis for the autoimmune response, while environmental factors ultimately lead to progressive destruction of thyroid follicular cells by breaching the threshold of immune tolerance.
Clinical presentation and diagnosis
Hashimoto’s thyroiditis is a chronic inflammatory disease characterized by an autoimmune attack specific to the thyroid, with a highly variable clinical presentation ranging from an asymptomatic subclinical state to significant hypothyroidism. As the disease advances, lymphocytic infiltration of the thyroid tissue and destruction of follicular cells can cause the thyroid to enlarge or atrophy, ultimately leading to abnormal thyroid function (40). Because early symptoms are often vague and nonspecific, clinical diagnosis frequently depends on serological markers [e.g., antithyroid peroxidase antibody (TPOAb), antithyroglobulin antibody (TGAb)], imaging, and evaluation of thyroid function. Symptoms of HT can be local or systemic. Local symptoms mainly result from compression caused by an enlarged thyroid gland, such as tracheal compression. Systemic symptoms are primarily due to hypothyroidism, as the hormones produced by the thyroid are insufficient to meet the needs of peripheral tissues (6, 41).
The diagnosis of the disease is mainly dependent on clinical symptoms and the presence of TPOAb, which is positive in about 95% of Hashimoto patients (6). When TPOAb and TGAb are overexpressed, IgG4 is informative for diagnosis and typing assessment (29). Whereas in TPOAb-negative patients, ultrasound plays an important role, the ultrasound features of HT patients include glandular echogenicity, inhomogeneity, abundant blood flow, and the presence of small cysts (40). Ultrasound is also used to differentiate HT from other thyroid diseases (42). Due to the low resolution and relatively more extraneous noise of conventional ultrasound, the feature-level enhanced integrated network (FBENet) was introduced to solve these problems with an average accuracy of 82.92%. FBENet is a deep learning model designed to accurately distinguish Hashimoto’s thyroiditis from normal thyroid tissue in ultrasound images (43). In conclusion, for the diagnosis of HT, the combination of ultrasound and thyroid antibody test results is more informative (44, 45).
Treatment and management
The key to the current treatment of HT is the regulation of thyroid hormones as a means of improving thyroid function and thereby slowing the progression of the disease. When the patient does not have thyroid function changes, it is often sufficient to follow the patient with follow-up visits to monitor changes in thyroid function. When hypothyroidism occurs, hormone replacement is often achieved with oral Levo-thyroxine 4 (LT4) tablets, which need to be taken for life (40). LT4 can partially reverse HT-induced muscular, renal, and lipid dysfunctions and significantly reduce the symptoms associated with HT in patients (46). However, even with oral LT4 hormone replacement therapy, some clinical symptoms persist, such as fatigue, arthralgia, dry eyes, dry mouth, etc (47). Therefore, LT4 and T3 combination therapy has been proposed. Combined with fourteen published studies showed that the combination did not show significant benefits (48), so this option is still controversial (40). In addition to Western drug therapy, traditional Chinese medicine (TCM) also plays an important role in the treatment of this disease. More and more studies have shown that certain Chinese medicines have better efficacy in lowering the level of thyroid antibodies and improving clinical symptoms, such as Chai Xiang Dispersing Knot Granules, Xia Kou Dispersing Gall Soup, Dispersing Knot Soup for Galls, and Xiaoyao-san (49, 50); according to a randomized controlled study, Xiaoyao-san preparation were able to significantly lower the level of TPOAb, and reduce antibody levels (when combined with LT4, it could even more closely reduce antibody levels (51). In addition, some studies have shown that traditional Chinese medicine acupoints can improve the clinical symptoms of patients with this disease and can also reduce the level of serum antibodies, thus slowing down the process of clinical hypothyroidism in patients (52). In addition to pharmacological treatment, studies have also shown that total thyroidectomy is decisive for improving the relief of autoimmune features such as vitiligo, pernicious anemia, thrombocytopenia, etc., exhibited by HT (53), but at present, HT exhibits a variety of immune-related features that have not been included in the indications for surgery.
Selenium supplementation is also currently important in the treatment of clinical HT as an element that plays a crucial role in the secretion of thyroid hormones. Selenium supplements can restore thyroid function to normal in some patients with subclinical hypothyroidism (54). The addition of selenium to the treatment regimen for Hashimoto’s thyroiditis, as shown in a prospective randomized controlled study, led to a significant reduction in TPOAb and TGAb levels in these patients (33). Since vitamin D is involved in the development of the disease, vitamin D supplementation has also been shown to be important in the treatment of thyroid dysfunction (32). Although it does not improve the function of the thyroid gland itself, it can change the titer of TPOAb (55),a prospective, randomized, controlled clinical study demonstrated that after 6 months of vitamin D supplementation therapy (both vitamin D alone and vitamin D in combination with LT4) resulted in thyroid peroxidase antibody compared to untreated controls a significant reduction in titre levels (56). In addition, lifestyle interventions play a pivotal role in the treatment of the disease. For example, excessive iodine intake can induce thyroid autoimmunity by increasing the immunogenicity of Tg in genetically susceptible individuals, and HT patients should avoid a high iodine diet (57). Furthermore, many researchers have suggested that other diets are also beneficial for patients with the disease, e.g., low-carbohydrate diets, gluten-free diets, etc (58–60); according to a meta-analysis, continuing for 6 months helped people on a gluten-free diet improve thyroid function, reduce thyroid inflammation levels, and lower antibody levels (61).
Summary and future perspectives
The pathogenesis of HT involves a complex interaction of genetic susceptibility, immune regulation, and environmental factors. In recent years, with the continuous development of science and technology, our understanding of the disease has deepened, and the diagnosis and treatment of the disease are no longer limited. However, this is far from enough, and we need to further explore, for example, new biomarkers that can assess the efficacy of treatment and the mechanisms of action of different therapeutic approaches. Due to the TPOAb/TgAb assay limitations, it is recommended to develop a composite marker that combines immunocytology and imaging. And predict the value of this marker for the regression of subclinical hypothyroidism should be verified by a prospective cohort. For patients in the subclinical stage, based on are recommended immunocytology randomized controlled trails to immune markers assess selenium supplementation whether immunomodulatory regimens such as can delay disease progression by regulating the Treg/Th17 balance. For the clinical efficacy of traditional Chinese medicine, such as Xiaoyao-san, it is recommended to verify whether the mechanism of action is carried out by regulating the balance of Treg/Th17 through animal experiments. And to clarify the mechanism of intestinal flora in lowering the level of thyroid antibodies. Through the above pathways, it may be possible to promote the transformation of HT diagnosis and treatment from passive replacement to active intervention, and from vague diagnosis to precision medicine. This still requires the joint participation and unremitting efforts of medical workers and researchers.
Author contributions
LW: Conceptualization, Investigation, Writing – original draft. XZ: Data curation, Investigation, Writing – original draft. SX: Data curation, Investigation, Methodology, Writing – review & editing. BZ: Formal analysis, Methodology, Writing – review & editing. YW: Data curation, Resources, Writing – review & editing. ZL: Project administration, Writing – review & editing. YZ: Project administration, Writing – review & editing. SL: Visualization, Writing – review & editing. FC: Resources, Writing – review & editing. LZ: Conceptualization, Formal analysis, Project administration, Resources, Writing – original draft, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This study was supported by Zhejiang Provincial Natural Science Foundation of China (Grant No. LTGY24H070004), Lishui Municipal Science and Technology Program (Grant No.2023GYX05), the Medical and Health Research Program of Zhejiang Province (Grant No. 2023KY420).
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Tywanek E, Michalak A, Świrska J, and Zwolak A. Autoimmunity, new potential biomarkers and the thyroid gland-the perspective of hashimoto's thyroiditis and its treatment. Int J Mol Sci. (2024) 25:4703. doi: 10.3390/ijms25094703
2. Taylor PN, Medici MM, Hubalewska-Dydejczyk A, and Boelaert K. Hypothyroidism. Lancet. (2024) 404:1347–64. doi: 10.1016/S0140-6736(24)01614-3
3. Jonklaas J. Optimal thyroid hormone replacement. Endocr Rev. (2022) 43:366–404. doi: 10.1210/endrev/bnab031
4. Martínez-Hernández R, Sánchez de la Blanca N, Sacristán-Gómez P, Serrano-Somavilla A, Muñoz De Nova JL, Sánchez Cabo F, et al. Unraveling the molecular architecture of autoimmune thyroid diseases at spatial resolution. Nat Commun. (2024) 15:5895. doi: 10.1038/s41467-024-50192-5
5. Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. (2023) 401:1878–90. doi: 10.1016/S0140-6736(23)00457-9
6. Ralli M, Angeletti D, Fiore M, D'Aguanno V, Lambiase A, Artico M, et al. Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential Malignant transformation. Autoimmun Rev. (2020) 19:102649. doi: 10.1016/j.autrev.2020.102649
7. Zhang QY, Ye XP, Zhou Z, Zhu CF, Li R, Fang Y, et al. Lymphocyte infiltration and thyrocyte destruction are driven by stromal and immune cell components in Hashimoto's thyroiditis. Nat Commun. (2022) 13:775. doi: 10.1038/s41467-022-28120-2
8. Chai Y and Liu B. The progress of diagnosis and surgical treatment on Hashimoto thyroiditis. Chin Contemp Med. (2015) 22:19–22.
9. Vargas-Uricoechea H, Castellanos-Pinedo A, Urrego-Noguera K, Pinzón-Fernández MV, Meza-Cabrera IA, and Vargas-Sierra H. A scoping review on the prevalence of hashimoto's thyroiditis and the possible associated factors. Med Sci (Basel). (2025) 13:43. doi: 10.37766/inplasy2025.3.0049
10. Feldt-Rasmussen U. Hashimoto's thyroiditis as a risk factor for thyroid cancer. Curr Opin Endocrinol Diabetes Obes. (2020) 27:364–71. doi: 10.1097/MED.0000000000000570
11. Wang Y, Fang S, and Zhou H. Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms. Best Pract Res Clin Endocrinol Metab. (2023) 37:101743. doi: 10.1016/j.beem.2023.101743
12. Milo T, Korem Kohanim Y, Toledano Y, Toledano Y, and Alon U. Autoimmune thyroid diseases as a cost of physiological autoimmune surveillance. Trends Immunol. (2023) 44:365–71. doi: 10.1016/j.it.2023.03.007
13. Yao Z, Guo F, Tan Y, Zhang Y, Geng Y, Yang G, et al. Causal relationship between inflammatory cytokines and autoimmune thyroid disease: a bidirectional two-sample Mendelian randomization analysis. Front Immunol. (2024) 15:1334772. doi: 10.3389/fimmu.2024.1334772
14. Mazzieri A, Montanucci P, Basta G, and Calafiore R. The role behind the scenes of Tregs and Th17s in Hashimoto's thyroiditis: Toward a pivotal role of FOXP3 and BACH2. Front Immunol. (2022) 13:1098243. doi: 10.3389/fimmu.2022.1098243
15. Yang M, Sun B, Li J, Yang B, Xu J, Zhou X, et al. Alteration of the intestinal flora may participate in the development of Graves' disease: a study conducted among the Han population in southwest China. Endocr Connect. (2019) 8:822–8. doi: 10.1530/EC-19-0001
16. Gong B, Wang C, Meng F, Wang H, Song B, Yang Y, et al. Association between gut microbiota and autoimmune thyroid disease: A systematic review and meta-analysis. Front Endocrinol (Lausanne). (2021) 12:774362. doi: 10.3389/fendo.2021.774362
17. Moens H, Farid NR, Sampson L, Noel EP, and Barnard JM. Hashimoto's thyroiditis is associated with HLA-DRw3. N Engl J Med. (1978) 299:133–4. doi: 10.1056/NEJM197807202990306
18. Lee HJ, Stefan-Lifshitz M, Li CW, and Tomer Y. Genetics and epigenetics of autoimmune thyroid diseases: Translational implications. Best Pract Res Clin Endocrinol Metab. (2023) 37:101661. doi: 10.1016/j.beem.2022.101661
19. Kong YC, Lomo LC, Motte RW, Giraldo AA, Baisch J, Strauss G, et al. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene. J Exp Med. (1996) 184:1167–72. doi: 10.1084/jem.184.3.1167
20. Zhao Z, Gao Y, Pei X, Wang W, and Zhang H. Causal role of immune cells in Hashimoto's thyroiditis: Mendelian randomization study. Front Endocrinol (Lausanne). (2024) 15:1352616. doi: 10.3389/fendo.2024.1352616
21. Ban Y, Davies TF, Greenberg DA, Concepcion ES, and Tomer Y. The influence of human leucocyte antigen (HLA) genes on autoimmune thyroid disease (AITD): results of studies in HLA-DR3 positive AITD families. Clin Endocrinol (Oxf). (2002) 57:81–8. doi: 10.1046/j.1365-2265.2002.01566.x
22. Petrone A, Giorgi G, Mesturino CA, Capizzi M, Cascino I, Nistico L, et al. Association of DRB1*04-DQB1*0301 haplotype and lack of association of two polymorphic sites at CTLA-4 gene with Hashimoto's thyroiditis in an Italian population. Thyroid. (2001) 11:171–5. doi: 10.1089/105072501300042901
23. Roman SH, Greenberg D, Rubinstein P, Wallenstein S, and Davies TF. Genetics of autoimmune thyroid disease: lack of evidence for linkage to HLA within families. J Clin Endocrinol Metab. (1992) 74:496–503. doi: 10.1210/jcem.74.3.1740483
24. Santos LR, Durães C, Ziros PG, Pestana A, Esteves C, Neves C, et al. Interaction of genetic variations in NFE2L2 and SELENOS modulates the risk of hashimoto's thyroiditis. Thyroid. (2019) 29:1302–15. doi: 10.1089/thy.2018.0480
25. Akamizu T, Sale MM, Rich SS, Hiratani H, Noh JY, Kanamoto N, et al. Association of autoimmune thyroid disease with microsatellite markers for the thyrotropin receptor gene and CTLA-4 in Japanese patients. Thyroid. (2000) 10:851–8. doi: 10.1089/thy.2000.10.851
26. Fathima N, Narne P, and Ishaq M. Association and gene-gene interaction analyses for polymorphic variants in CTLA-4 and FOXP3 genes: role in susceptibility to autoimmune thyroid disease. Endocrine. (2019) 64:591–604. doi: 10.1007/s12020-019-01859-3
27. Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, Kern M, et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet. (2005) 76:561–71. doi: 10.1086/429096
28. Ehlers M, Thiel A, Bernecker C, Porwol D, Papewalis C, Willenberg HS, et al. Evidence of a combined cytotoxic thyroglobulin and thyroperoxidase epitope-specific cellular immunity in Hashimoto's thyroiditis. J Clin Endocrinol Metab. (2012) 97:1347–54. doi: 10.1210/jc.2011-2178
29. Lee HY, Liu Q, Jiang L, and Xia J. Application value of levels of serum Tpo Ab and Tg Ab in the diagnosis and classification of patients with Hashimoto's thyroiditis. Chin J OF Lab DIAGNOSIS. (2022) 26:176–9. doi: 10.3969/j.issn.1007-4287.2022.02.006
30. Fujii A, Inoue N, Watanabe M, Kawakami C, Hidaka Y, Hayashizaki Y, et al. TSHR gene polymorphisms in the enhancer regions are most strongly associated with the development of graves' Disease, especially intractable disease, and of hashimoto's disease. Thyroid. (2017) 27:111–9. doi: 10.1089/thy.2016.0345
31. Benvenga S and Guarneri F. Homology between TSH-R/Tg/TPO and Hashimoto's encephalopathy autoantigens. Front Biosci (Landmark Ed). (2020) 25:229–41. doi: 10.2741/4804
32. Kivity S, Agmon-Levin N, Zisappl M, Shapira Y, Nagy EV, Dankó K, et al. Vitamin D and autoimmune thyroid diseases. Cell Mol Immunol. (2011) 8:243–7. doi: 10.1038/cmi.2010.73
33. Hu Y, Feng W, Chen H, Shi H, Jiang L, Zheng X, et al. Effect of selenium on thyroid autoimmunity and regulatory T cells in patients with Hashimoto's thyroiditis: A prospective randomized-controlled trial. Clin Transl Sci. (2021) 14:1390–402. doi: 10.1111/cts.12993
34. Nourbakhsh M, Ahmadpour F, Chahardoli B, Malekpour-Dehkordi Z, Nourbakhsh M, Hosseini-Fard SR, et al. Selenium and its relationship with selenoprotein P and glutathione peroxidase in children and adolescents with Hashimoto's thyroiditis and hypothyroidism. J Trace Elem Med Biol. (2016) 34:10–4. doi: 10.1016/j.jtemb.2015.10.003
35. Ludgate ME, Masetti G, and Soares P. The relationship between the gut microbiota and thyroid disorders. Nat Rev Endocrinol. (2024) 20:511–25. doi: 10.1038/s41574-024-01003-w
36. Rayman MP. Multiple nutritional factors and thyroid disease, with particular reference to autoimmune thyroid disease. Proc Nutr Soc. (2019) 78:34–44. doi: 10.1017/S0029665118001192
37. Teng W, Shan Z, Teng X, Guan H, Li Y, Teng D, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med. (2006) 354:2783–93. doi: 10.1056/NEJMoa054022
38. Lim DW, Choi MS, and Kim SM. Bioinformatics and connectivity map analysis suggest viral infection as a critical causative factor of hashimoto's thyroiditis. Int J Mol Sci. (2023) 24:1157. doi: 10.3390/ijms24021157
39. D'aurizio F, Villalta D, Metus P, Doretto P, and Tozzoli R. Is vitamin D a player or not in the pathophysiology of autoimmune thyroid diseases? Autoimmun Rev. (2015) 14:363–9. doi: 10.1016/j.autrev.2014.10.008
40. Klubo-Gwiezdzinska J and Wartofsky L. Hashimoto thyroiditis: an evidence-based guide to etiology, diagnosis and treatment. Pol Arch Intern Med. (2022) 132:16222. doi: 10.20452/pamw.16222
42. Huang PH. Application of color doppler ultrasound in differential diagnosis of hashimoto's thyroiditis and hyperthyroidism. Chin Med device Inf. (2023) 29:96–8. doi: 10.3969/j.issn.1006-6586.2023.10.032
43. Jiang W, Luo T, Liang Z, Chen K, He J, Zhao Z, et al. FBENet: feature-level boosting ensemble network for hashimoto's thyroiditis ultrasound image classification. IEEE J BioMed Health Inform. (2024) 28:5360–9. doi: 10.1109/JBHI.2024.3414389
44. Wu DD and Yu XH. Differentiable analysis of high-resolution ultrasound and thyroid autoantibody diagnosis of Hashimoto’s thyroiditis. Chin Rural Med. (2023) 30:3–4. doi: 10.3969/j.issn.1006-5180.2023.10.002
45. Zhao CQ, Xie L, Zhang M, and Guo J. Value of routine ultrasound combined with serum thyroglobulin antibody level in diagnosis of Hashimoto's thyroiditis. Int Med Health Guidance New’s. (2023) 29:3571–5. doi: 10.3760/cma.j.issn.1007-1245.2023.24.010
46. Li X and Cao C. Levothyroxine sodium tablets reversed Hashimoto thyroiditis-induced kidney injury, muscle injury, and lipid metabolism disorder: A case report and literature review. Med (Baltimore). (2024) 103:e39190. doi: 10.1097/MD.0000000000039190
47. Walsh JP, Ward LC, Burke V, Bhagat CI, Shiels L, Henley D, et al. Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial. J Clin Endocrinol Metab. (2006) 91:2624–30. doi: 10.1210/jc.2006-0099
48. Jonklaas J, Bianco AC, Cappola AR, Celi FS, Fliers E, Heuer H, et al. Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: A consensus document. Thyroid. (2021) 31:156–82. doi: 10.1089/thy.2020.0720
49. Luo J, Zhou L, Sun A, Yang H, Zhang P, Liu K, et al. Herbal medicine for Hashimoto's thyroiditis: A systematic review and network meta-analysis. J Ethnopharmacol. (2024) 323:117663. doi: 10.1016/j.jep.2023.117663
50. Niu Y, Zhang HY, Deng B, Liu Y, and Li M. Research progress of chinese and western medicine treatment of hashimoto's thyroiditis. J Med Inf. (2025) 38:188–92. doi: 10.3969/j.issn.1006-1959.2025.02.038
51. Wang C, Ma W, Qin L, Wu L, and Liu T. Efficacy of Xiaoyao-san preparations in treating Hashimoto's thyroiditis: a meta-analysis and systematic review. Front Pharmacol. (2025) 16:1528506. doi: 10.3389/fphar.2025.1528506
52. Qiao X. Clinical research on the treatment of Hashimoto’s thyroiditis with traditional Chinese medicine acupoint application. Jinan, Shandong, China: Shandong University of Traditional Chinese Medicine (2024).
53. Panchangam RB, Kota SK, Mayilvaganan S, and Kuravi BG. What is the impact of thyroidectomy on autoimmune features associated with Hashimoto's thyroiditis?-Institutional experience. Niger J Clin Pract. (2021) 24:905–10. doi: 10.4103/njcp.njcp_426_20
54. Pirola I, Gandossi E, Agosti B, Delbarba A, and Cappelli C. Selenium supplementation could restore euthyroidism in subclinical hypothyroid patients with autoimmune thyroiditis. Endokrynol Pol. (2016) 67:567–71. doi: 10.5603/EP.2016.0064
55. Jiang H, Chen X, Qian X, and Shao S. Effects of vitamin D treatment on thyroid function and autoimmunity markers in patients with Hashimoto's thyroiditis-A meta-analysis of randomized controlled trials. J Clin Pharm Ther. (2022) 47:767–75. doi: 10.1111/jcpt.13605
56. Jiang X, Huang Y, Li Y, Xia Y, Liu L, Lin F, et al. Therapeutic effect of vitamin D in Hashimoto's thyroiditis: a prospective, randomized and controlled clinical trial in China. Am J Transl Res. (2023) 15:6234–41.
57. Carayanniotis G. Recognition of thyroglobulin by T cells: the role of iodine. Thyroid. (2007) 17:963–73. doi: 10.1089/thy.2007.0199
58. Huang XS, Dai N, Xu JX, Xiang JY, Zheng XZ, Ke TY, et al. MRI quantitative assessment of the effects of low-carbohydrate therapy on Hashimoto's thyroiditis. Endocr Connect. (2024) 13:e230477. doi: 10.1530/EC-23-0477
59. Knezevic J, Starchl C, Tmava Berisha A, and Amrein K. Thyroid-gut-axis: how does the microbiota influence thyroid function? Nutrients. (2020) 12:1769. doi: 10.3390/nu12061769
60. Rodziewicz A, Szewczyk A, and Bryl E. Gluten-free diet alters the gut microbiome in women with autoimmune thyroiditis. Nutrients. (2024) 16:685. doi: 10.3390/nu16050685
Keywords: autoimmunity, Hashimoto’s thyroiditis, hypothyroidism, immunomodulation, thyroglobulin antibody, thyroid peroxidase antibody
Citation: Wang L, Zhu X, Xu S, Zhou B, Wu Y, Li Z, Zhao Y, Li S, Cheng F and Zhu L (2026) Hashimoto’s thyroiditis: from pathogenesis to clinical management. Front. Endocrinol. 17:1729316. doi: 10.3389/fendo.2026.1729316
Received: 21 October 2025; Accepted: 05 January 2026; Revised: 28 December 2025;
Published: 02 February 2026.
Edited by:
Xuqin Zheng, Nanjing Medical University, ChinaReviewed by:
Dai Cui, Nanjing Medical University, ChinaCopyright © 2026 Wang, Zhu, Xu, Zhou, Wu, Li, Zhao, Li, Cheng and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lei Zhu, RHJfemxlaUAxNjMuY29t
†These authors have contributed equally to this work